Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 10, Issue 11, Pages 1841-1845Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14656560903048959
Keywords
bupropion; naltrexone; pharmacotherapy; weight loss
Categories
Ask authors/readers for more resources
Since their discovery in the brain and gastrointestinal tract nearly 40 years ago, endogenous opioid peptides have been progressively shown to play a role in the regulation of food intake. Animal and human studies regarding opioid peptides and ingestive behavior are reviewed. While the opioid receptor antagonist naltrexone is associated with minimal weight loss as monotherapy, it does have potential utility in the treatment of obesity when combined with the pro-opiomelanocortin activator bupropion.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available